Wall Street Journal - Merck said its third-quarter profit soared 62% on higher sales of vaccines and drugs for asthma and diabetes, and a lower reserve for product-liability litigation. Sales declined for cholesterol drug Zocor, which had been Merck's best-selling product ...
